Novartis studying pancreatic cancer drug

FRANKFURT, Germany Novartis may license a MediGene drug for treating pancreatic cancer, according to Reuters.

The drug, EndoTAG, would allow the Swiss drug maker to compete with Eli Lilly, Roche and Pfizer. Studies of the drug have shown that the drug can prolong the lives of pancreatic cancer patients who receive the drug in addition to chemotherapy.